pyrazinamide has been researched along with linezolid in 33 studies
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 0 (0.00) | 18.2507 |
| 2000's | 2 (6.06) | 29.6817 |
| 2010's | 17 (51.52) | 24.3611 |
| 2020's | 14 (42.42) | 2.80 |
| Authors | Studies |
|---|---|
| Cho, SH; Franzblau, SG; Hwang, CH; Pauli, GF; Wan, B; Warit, S | 1 |
| Gaillard, JL; Jackson, M; McDonnell, G; Niederweis, M; Skovierová, H; Svetlíková, Z | 1 |
| Angulo-Barturen, I; Beltrán, M; Cáceres, N; Cardona, PJ; García, JI; García-Bustos, JF; Rullas, J | 1 |
| Afshari, CA; Chen, Y; Dunn, RT; Hamadeh, HK; Kalanzi, J; Kalyanaraman, N; Morgan, RE; van Staden, CJ | 1 |
| Chen, M; Hu, C; Suzuki, A; Thakkar, S; Tong, W; Yu, K | 1 |
| Abouelhassan, Y; Bai, F; Burch, GM; Garrison, AT; Huigens, RW; Jin, S; Kallifidas, D; Luesch, H; Nguyen, MT; Norwood, VM; Rolfe, M | 1 |
| Chang, L; Feng, LS; Gao, C; Lv, ZS; Ren, QC; Xu, Z; Zhang, S | 1 |
| Abouelhassan, Y; Garrison, AT; Huigens, RW; Jin, S; Kallifidas, D; Kim, YS; Luesch, H; Tan, H | 1 |
| Mabhula, A; Singh, V | 1 |
| Bedarida, G; Campbell, S; Jakubiec, W; Kumar, V; Ladutko, L; Miller, PF; Mitton-Fry, M; Paige, D; Silvia, A; Wallis, RS; Zhu, T | 1 |
| Betoudji, F; Converse, PJ; Dartois, V; Li, SY; Mdluli, KE; Mendel, CM; Nuermberger, EL; Tasneen, R; Tyagi, S; Williams, K; Yang, T | 1 |
| Jung, JA; Kaisar, N; Parvez, MM; Shin, HJ; Shin, JG | 1 |
| Fu, L; Guo, Z; Li, P; Liu, S; Mu, X; Wang, B; Zhao, W; Zheng, M | 1 |
| Blackmore, T; McNaughton, A; McNaughton, H | 1 |
| Mendel, C; Murray, S; Spigelman, M | 1 |
| Ahn, H; Cho, YJ; Choi, HS; Choi, SM; Hahn, S; Han, J; Heo, EY; Hwang, YR; Jeong, I; Jo, YS; Joh, JS; Ki, J; Kim, DK; Kim, H; Kim, HS; Kim, J; Kim, SJ; Kwak, N; Lee, CH; Lee, J; Lee, JH; Lee, JK; Lee, JY; Lee, M; Lee, SH; Lee, SM; Lee, YJ; Lim, JN; Park, JH; Park, JS; Park, SS; Park, YS; Song, T; Yim, JJ; Yoon, HI | 1 |
| Ahn, H; Ahn, JH; Cho, SN; Hahn, S; Jang, JY; Jeon, D; Jhun, BW; Jo, KW; Kang, YA; Kim, CK; Kim, DK; Kim, JS; Kim, SY; Kim, YR; Koh, WJ; Lee, JH; Lee, JY; Lee, M; Lee, SH; Lee, T; Mok, J; Park, JS; Shim, TS; Shin, S; Shin, SJ; Song, T; Won, HJ; Yim, JJ | 1 |
| Bang, H; Barry, CE; Dartois, V; Eum, S; Fox, WS; Gupta, SV; Lee, M; Savic, RM; Shim, T; Strydom, N; Via, LE; Zimmerman, M | 1 |
| Del Parigi, A; Everitt, D; Li, H; Li, M; Mendel, C; Nedelman, JR; Salinger, DH | 1 |
| Cobelens, F; van den Hof, S; Wang, S; Xia, H; Zhao, B; Zhao, Y; Zhou, Y | 1 |
| Burger, DA; Dawson, R; De Jager, VR; Diacon, AH; Everitt, D; Mendel, CM; Narunsky, K; Nedelman, J; Pappas, F; Vanker, N | 1 |
| Dhamija, RK; Garg, D; Saroha, D; Singh, AK | 1 |
| E R, V; Keny, S; Lawande, D; Parrikar, A | 1 |
| Bax, HI; de Steenwinkel, JEM; Keutzer, L; Pieterman, ED; Simonsson, USH; van den Berg, S; van der Meijden, A; Wang, H; Zimmerman, MD | 1 |
| Basdeo, SA; Cahill, C; Cox, DJ; Gogan, KM; Gordon, SV; Keane, J; O'Connell, F; O'Sullivan, J; Phelan, JJ | 1 |
| de Jong, BC; Decroo, T; Gils, T; Lynen, L; Van Deun, A | 1 |
| Jiang, H; Li, X; Niu, Q; Xing, Z; Xu, J | 1 |
| Chen, X; Ding, Y; Fu, L; Guo, S; Liu, H; Lu, Y; Wang, B; Wang, N; Zhang, W; Zhu, H | 1 |
| Kamoshita, F; Karaushi, H; Mitsutake, K; Miyawaki, Y; Seki, M; Watanabe, N | 1 |
| Ahn, JH; Cho, SN; Hahn, S; Jeon, D; Jhun, BW; Jo, KW; Kang, YA; Kim, DK; Kim, J; Kim, JS; Kim, K; Kim, S; Kim, SY; Kim, YR; Kwak, N; Lee, JK; Lee, JY; Lee, M; Lee, SH; Lee, T; Mok, J; Park, JS; Seok, KH; Shim, TS; Yim, D; Yim, JJ; Yoon, S | 1 |
| Avihingsanon, A; Balanag, VM; Burhan, E; Chew, KL; Cousins, C; Crook, AM; Dalay, VB; Djaharuddin, I; Kusmiati, T; Lee, SL; Lu, Q; Nunn, AJ; Papineni, P; Paton, NI; Pokharkar, Y; Ruslami, R; Sarin, R; Sekaggya-Wiltshire, C; Sugiri, JJR; Suresh, C; Veto, RS | 1 |
| Aalhoul, F; Cotton, F; Fage, D | 1 |
| Adeel, A; Ahmad, A; Ahmad, I; Aslam, H; Mushtaq, F; Raza, SM; Saleem, S | 1 |
4 review(s) available for pyrazinamide and linezolid
| Article | Year |
|---|---|
DILIrank: the largest reference drug list ranked by the risk for developing drug-induced liver injury in humans.
Topics: Chemical and Drug Induced Liver Injury; Databases, Factual; Drug Labeling; Humans; Pharmaceutical Preparations; Risk | 2016 |
Triazole derivatives and their anti-tubercular activity.
Topics: Antitubercular Agents; Dose-Response Relationship, Drug; Humans; Microbial Sensitivity Tests; Molecular Structure; Mycobacterium tuberculosis; Structure-Activity Relationship; Triazoles; Tuberculosis | 2017 |
Drug-resistance in
Topics: | 2019 |
Pretomanid for tuberculosis: a systematic review.
Topics: Antitubercular Agents; Humans; Linezolid; Moxifloxacin; Nitroimidazoles; Pyrazinamide; Randomized Controlled Trials as Topic; Rifampin; Tuberculosis; Tuberculosis, Multidrug-Resistant | 2022 |
7 trial(s) available for pyrazinamide and linezolid
| Article | Year |
|---|---|
Biomarker-assisted dose selection for safety and efficacy in early development of PNU-100480 for tuberculosis.
Topics: Acetamides; Adolescent; Adult; Animals; Antitubercular Agents; Area Under Curve; Dose-Response Relationship, Drug; Drug Administration Schedule; Humans; Linezolid; Microbial Sensitivity Tests; Middle Aged; Mycobacterium tuberculosis; Oxazolidinones; Pyrazinamide; Rats; Serum Bactericidal Test; Treatment Outcome; Tuberculosis; Young Adult | 2011 |
Substitution of ethambutol with linezolid during the intensive phase of treatment of pulmonary tuberculosis: a prospective, multicentre, randomised, open-label, phase 2 trial.
Topics: Adult; Aged; Aged, 80 and over; Antitubercular Agents; Drug Substitution; Drug Therapy, Combination; Ethambutol; Female; Humans; Isoniazid; Linezolid; Male; Middle Aged; Prospective Studies; Pyrazinamide; Rifampin; Sputum; Treatment Outcome; Tuberculosis, Multidrug-Resistant; Tuberculosis, Pulmonary; Young Adult | 2019 |
Delamanid, linezolid, levofloxacin, and pyrazinamide for the treatment of patients with fluoroquinolone-sensitive multidrug-resistant tuberculosis (Treatment Shortening of MDR-TB Using Existing and New Drugs, MDR-END): study protocol for a phase II/III, m
Topics: Adult; Aged; Aged, 80 and over; Antitubercular Agents; Clinical Trials, Phase II as Topic; Clinical Trials, Phase III as Topic; Drug Administration Schedule; Drug Resistance, Multiple, Bacterial; Drug Therapy, Combination; Equivalence Trials as Topic; Female; Humans; Levofloxacin; Linezolid; Male; Middle Aged; Multicenter Studies as Topic; Mycobacterium tuberculosis; Nitroimidazoles; Oxazoles; Pyrazinamide; Republic of Korea; Time Factors; Treatment Outcome; Tuberculosis, Multidrug-Resistant; Tuberculosis, Pulmonary; Young Adult | 2019 |
Long-Term Effects on QT Prolongation of Pretomanid Alone and in Combinations in Patients with Tuberculosis.
Topics: Antitubercular Agents; Computer Simulation; Diarylquinolines; Double-Blind Method; Drug Therapy, Combination; Electrocardiography; Heart Rate; Humans; Linezolid; Long QT Syndrome; Models, Statistical; Moxifloxacin; Mycobacterium tuberculosis; Nitroimidazoles; Pyrazinamide; Tuberculosis, Multidrug-Resistant | 2019 |
Fourteen-Day Bactericidal Activity, Safety, and Pharmacokinetics of Linezolid in Adults with Drug-Sensitive Pulmonary Tuberculosis.
Topics: Adult; Antitubercular Agents; Drug Therapy, Combination; Ethambutol; Female; Humans; Isoniazid; Linezolid; Male; Microbial Sensitivity Tests; Mycobacterium tuberculosis; Pyrazinamide; Rifampin; South Africa; Sputum; Tuberculosis, Pulmonary | 2020 |
9 months of delamanid, linezolid, levofloxacin, and pyrazinamide versus conventional therapy for treatment of fluoroquinolone-sensitive multidrug-resistant tuberculosis (MDR-END): a multicentre, randomised, open-label phase 2/3 non-inferiority trial in So
Topics: Antitubercular Agents; Drug Therapy, Combination; Female; Fluoroquinolones; Humans; Levofloxacin; Linezolid; Male; Pyrazinamide; Treatment Outcome; Tuberculosis, Multidrug-Resistant | 2022 |
Treatment Strategy for Rifampin-Susceptible Tuberculosis.
Topics: Antitubercular Agents; Diarylquinolines; Drug Administration Schedule; Drug Therapy, Combination; Ethambutol; Humans; Isoniazid; Linezolid; Pyrazinamide; Rifampin; Treatment Outcome; Tuberculosis, Multidrug-Resistant; Tuberculosis, Pulmonary | 2023 |
22 other study(ies) available for pyrazinamide and linezolid
| Article | Year |
|---|---|
Low-oxygen-recovery assay for high-throughput screening of compounds against nonreplicating Mycobacterium tuberculosis.
Topics: Anti-Bacterial Agents; Antitubercular Agents; DNA, Bacterial; Drug Evaluation, Preclinical; Mycobacterium tuberculosis; Oxygen | 2007 |
Role of porins in the susceptibility of Mycobacterium smegmatis and Mycobacterium chelonae to aldehyde-based disinfectants and drugs.
Topics: Antitubercular Agents; Disinfectants; Drug Resistance, Bacterial; Glutaral; Microbial Sensitivity Tests; Molecular Sequence Data; Mutation; Mycobacterium chelonae; Mycobacterium smegmatis; o-Phthalaldehyde; Porins | 2009 |
Fast standardized therapeutic-efficacy assay for drug discovery against tuberculosis.
Topics: Acetamides; Animals; Antitubercular Agents; Aza Compounds; Disease Models, Animal; Drug Discovery; Ethambutol; Fluoroquinolones; Immunocompetence; Inhalation Exposure; Isoniazid; Linezolid; Mice; Mice, Inbred C57BL; Moxifloxacin; Oxazolidinones; Pyrazinamide; Quinolines; Reproducibility of Results; Rifampin; Tuberculosis, Pulmonary | 2010 |
A multifactorial approach to hepatobiliary transporter assessment enables improved therapeutic compound development.
Topics: Animals; ATP Binding Cassette Transporter, Subfamily B; ATP Binding Cassette Transporter, Subfamily B, Member 11; ATP-Binding Cassette Transporters; Biological Transport; Chemical and Drug Induced Liver Injury; Cluster Analysis; Drug-Related Side Effects and Adverse Reactions; Humans; Liver; Male; Multidrug Resistance-Associated Proteins; Pharmacokinetics; Rats; Rats, Sprague-Dawley; Recombinant Proteins; Risk Assessment; Risk Factors; Toxicity Tests | 2013 |
Structure-Activity Relationships of a Diverse Class of Halogenated Phenazines That Targets Persistent, Antibiotic-Tolerant Bacterial Biofilms and Mycobacterium tuberculosis.
Topics: Biofilms; Carbon-13 Magnetic Resonance Spectroscopy; Drug Resistance, Bacterial; Drug Screening Assays, Antitumor; Halogens; HeLa Cells; Humans; Microbial Sensitivity Tests; Mycobacterium tuberculosis; Phenazines; Proton Magnetic Resonance Spectroscopy; Structure-Activity Relationship | 2016 |
An Efficient Buchwald-Hartwig/Reductive Cyclization for the Scaffold Diversification of Halogenated Phenazines: Potent Antibacterial Targeting, Biofilm Eradication, and Prodrug Exploration.
Topics: Anti-Bacterial Agents; Biofilms; Cyclization; Halogenation; HeLa Cells; Humans; Methicillin-Resistant Staphylococcus aureus; Microbial Sensitivity Tests; Phenazines | 2018 |
Contribution of Oxazolidinones to the Efficacy of Novel Regimens Containing Bedaquiline and Pretomanid in a Mouse Model of Tuberculosis.
Topics: Animals; Antitubercular Agents; Bacterial Load; Diarylquinolines; Disease Models, Animal; Drug Administration Schedule; Drug Combinations; Drug Resistance, Multiple, Bacterial; Drug Synergism; Female; Linezolid; Lung; Mice; Mice, Inbred BALB C; Mycobacterium tuberculosis; Nitroimidazoles; Organophosphates; Oxazoles; Oxazolidinones; Pyrazinamide; Time Factors; Treatment Outcome; Tuberculosis, Pulmonary | 2016 |
Inhibitory Interaction Potential of 22 Antituberculosis Drugs on Organic Anion and Cation Transporters of the SLC22A Family.
Topics: 1-Methyl-4-phenylpyridinium; Aminosalicylic Acid; Animals; Antitubercular Agents; Ciprofloxacin; HEK293 Cells; Humans; Inhibitory Concentration 50; Ion Transport; Kinetics; Levofloxacin; Linezolid; Metformin; Octamer Transcription Factor-1; Organic Anion Transport Protein 1; Organic Anion Transporters, Sodium-Independent; Organic Cation Transport Proteins; Organic Cation Transporter 2; Pyrazinamide; Rifabutin; Rifampin; Zidovudine | 2016 |
Interactions of linezolid and second-line anti-tuberculosis agents against multidrug-resistant Mycobacterium tuberculosis in vitro and in vivo.
Topics: Aminosalicylic Acid; Animals; Antitubercular Agents; Capreomycin; Drug Combinations; Drug Interactions; Humans; Isoniazid; Linezolid; Male; Mice, Inbred BALB C; Microbial Sensitivity Tests; Mycobacterium tuberculosis; Pyrazinamide; Rifampin; Tuberculosis, Multidrug-Resistant | 2016 |
Comprehensive cost of treating one patient with MDR/pre-XDR-TB in Wellington, New Zealand.
Topics: Adult; Amikacin; Aminosalicylic Acid; Anti-Bacterial Agents; Antitubercular Agents; Bronchoscopy; Clofazimine; Depression; Drug Costs; Emigrants and Immigrants; Ethambutol; Extensively Drug-Resistant Tuberculosis; Fluoroquinolones; Health Care Costs; Humans; India; Isoniazid; Linezolid; Male; Mediastinum; Microbial Sensitivity Tests; Moxifloxacin; New Zealand; Pyrazinamide; Radiography, Thoracic; Rifampin; Schizophrenia, Paranoid; Tuberculosis, Lymph Node; Tuberculosis, Multidrug-Resistant; Tuberculosis, Pleural; Tuberculosis, Pulmonary | 2016 |
TB Alliance regimen development for multidrug-resistant tuberculosis.
Topics: Antitubercular Agents; Clinical Protocols; Diarylquinolines; Dose-Response Relationship, Drug; Ethambutol; Extensively Drug-Resistant Tuberculosis; Fluoroquinolones; Humans; Isoniazid; Linezolid; Moxifloxacin; Nitroimidazoles; Pyrazinamide; Randomized Controlled Trials as Topic; Research Design; Rifampin; Tuberculosis, Multidrug-Resistant | 2016 |
Tuberculosis drugs' distribution and emergence of resistance in patient's lung lesions: A mechanistic model and tool for regimen and dose optimization.
Topics: Adult; Antitubercular Agents; Decision Support Techniques; Disease Progression; Drug Administration Schedule; Drug Dosage Calculations; Drug Resistance, Multiple, Bacterial; Drug Therapy, Combination; Female; Humans; Isoniazid; Kanamycin; Linezolid; Lung; Male; Middle Aged; Pyrazinamide; Retrospective Studies; Rifampin; Tissue Distribution; Treatment Failure; Tuberculosis, Multidrug-Resistant; Tuberculosis, Pulmonary; Young Adult | 2019 |
Value of pyrazinamide for composition of new treatment regimens for multidrug-resistant Mycobacterium tuberculosis in China.
Topics: Adult; Age Factors; Amidohydrolases; Antitubercular Agents; Base Sequence; China; Diarylquinolines; Genes, Bacterial; Genotype; Humans; Linezolid; Male; Microbial Sensitivity Tests; Middle Aged; Mycobacterium tuberculosis; Point Mutation; Polymorphism, Single Nucleotide; Prevalence; Pyrazinamide; Rifampin; Risk Factors; Tuberculosis, Multidrug-Resistant | 2020 |
Irreversible neuropathy in extremely-drug resistant tuberculosis: An unfortunate clinical conundrum.
Topics: Adult; Aminosalicylic Acid; Antitubercular Agents; Clofazimine; Cycloserine; Deprescriptions; Diarylquinolines; Ethionamide; Extensively Drug-Resistant Tuberculosis; Female; Humans; Kanamycin; Linezolid; Neural Conduction; Neurotoxicity Syndromes; Peripheral Nervous System Diseases; Pyrazinamide; Pyridoxine; Tuberculosis, Pulmonary | 2020 |
Gitelman-like syndrome: A rare complication of using aminoglycosides in tuberculosis - A case report.
Topics: Alkalosis; Antitubercular Agents; Capreomycin; Clofazimine; Cycloserine; Deprescriptions; Ethionamide; Gitelman Syndrome; Humans; Hypocalcemia; Hypokalemia; Levofloxacin; Linezolid; Male; Middle Aged; Pyrazinamide; Tuberculosis, Multidrug-Resistant; Tuberculosis, Pulmonary; Water-Electrolyte Imbalance | 2020 |
Superior Efficacy of a Bedaquiline, Delamanid, and Linezolid Combination Regimen in a Mouse Tuberculosis Model.
Topics: Animals; Antitubercular Agents; Diarylquinolines; Disease Models, Animal; Drug Therapy, Combination; Linezolid; Mice; Mycobacterium tuberculosis; Nitroimidazoles; Oxazoles; Pyrazinamide; Recurrence; Tuberculosis | 2021 |
The Iron Chelator Desferrioxamine Increases the Efficacy of Bedaquiline in Primary Human Macrophages Infected with BCG.
Topics: Amikacin; Antitubercular Agents; Bacterial Load; Cell Survival; Clofazimine; Cycloserine; Deferoxamine; Diarylquinolines; Drug Resistance, Bacterial; Drug Synergism; Gene Expression; Humans; Interferon-gamma; Interleukin-1beta; Interleukin-6; Iron; Iron Chelating Agents; Linezolid; Macrophages; Microbial Sensitivity Tests; Moxifloxacin; Mycobacterium bovis; Primary Cell Culture; Pyrazinamide | 2021 |
Intracellular Activity of Poly (DL-Lactide-co-Glycolide) Nanoparticles Encapsulated with Prothionamide, Pyrazinamide, Levofloxacin, Linezolid, or Ethambutol on Multidrug-Resistant
Topics: Anti-Bacterial Agents; Antitubercular Agents; Ethambutol; Humans; Levofloxacin; Linezolid; Mycobacterium tuberculosis; Nanoparticles; Polylactic Acid-Polyglycolic Acid Copolymer; Prothionamide; Pyrazinamide; Reactive Oxygen Species; Tuberculosis; Tuberculosis, Multidrug-Resistant | 2023 |
Superior Efficacy of a TBI-166, Bedaquiline, and Pyrazinamide Combination Regimen in a Murine Model of Tuberculosis.
Topics: Animals; Antitubercular Agents; Clofazimine; Diarylquinolines; Disease Models, Animal; Isoniazid; Linezolid; Mice; Mice, Inbred BALB C; Mycobacterium tuberculosis; Pyrazinamide; Rifampin; Tuberculosis; Tuberculosis, Multidrug-Resistant | 2022 |
A Mycobacterium tuberculosis-Infected Patient Who Could Not Tolerate Oral Intake Successfully Treated Using an Intravenous Tedizolid-Containing Regimen.
Topics: Aged; Anti-Bacterial Agents; Antitubercular Agents; Cutaneous Fistula; Ethambutol; Humans; Isoniazid; Levofloxacin; Linezolid; Male; Meropenem; Micafungin; Mycobacterium tuberculosis; Oxazolidinones; Pyrazinamide; Rifampin; Streptomycin; Teicoplanin; Tetrazoles; Tuberculosis | 2022 |
Protein binding investigation of first-line and second-line antituberculosis drugs.
Topics: Antitubercular Agents; Ethambutol; Humans; Isoniazid; Levofloxacin; Linezolid; Moxifloxacin; Protein Binding; Pyrazinamide; Rifampin; Tuberculosis | 2023 |
Antimicrobial drug resistant features of Mycobacterium tuberculosis associated with treatment failure.
Topics: Amikacin; Antitubercular Agents; Humans; Isoniazid; Linezolid; Microbial Sensitivity Tests; Moxifloxacin; Mutation; Mycobacterium tuberculosis; Pyrazinamide; Rifampin; Tuberculosis, Multidrug-Resistant; Verapamil | 2023 |